ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibodies"

  • Abstract Number: L02 • 2019 ACR/ARP Annual Meeting

    Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity

    Naizhuo Zhao 1, Audrey Smargiassi 2, Marianne Hatzopoulou 3, Ines Colmegna 4, Marie Hudson 5, Marvin Fritzler 6, Philip Awadalla 7 and Sasha Bernatsky8, 1Research Institute of the McGill University Health Centre, Montreal, Canada, 2University of Montreal, Montreal, Canada, 3University of Toronto, Toronto, Canada, 4McGill University Health Center, Montreal, QC, Canada, 5Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, Canada, 7Ontario Institute for Cancer Research, Toronto, Canada, 8Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
  • Abstract Number: 109 • 2019 ACR/ARP Annual Meeting

    Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis

    Yan Li 1, Jeffrey H. Ruth 2, Stephanie Rasmussen 3, Kalana S. Athukorala 2, Daniel P. Weber 2, M. Asif Amin 2, Phillip Campbell 3, Nora Singer 4, David Fox5 and Feng Lin 1, 1Cleveland Clinic, Cleveland, OH, 2University of Michigan, Ann Arbor, MI, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 4The MetroHealth System -Case Western Reserve University School of Medicine, Cleveland, OH, 5Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI

    Background/Purpose: CD6, an important regulator of T cell function, interacts with the ligands CD166 and CD318. We previously examined CD318 expression on synovial tissues (STs)…
  • Abstract Number: 964 • 2019 ACR/ARP Annual Meeting

    Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies

    Jennifer Young-Glazer1, Erin Wilfong 2, Peggy Kendall 1, Rachel Bonami 1 and Leslie Crofford 2, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University, Nashville

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
  • Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting

    New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Shinichi Nogi 4, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 5, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, 5Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
  • Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting

    Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice

    Fergus To1, Clara Ventín Rodríguez 2, Shuayb Elkhalifa 3, James Lilleker 4 and Hector Chinoy 4, 1University of British Columbia, Vancouver, Canada, 2Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 3(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, 4University of Manchester, Manchester, United Kingdom

    Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
  • Abstract Number: 1343 • 2018 ACR/ARHP Annual Meeting

    A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy

    Yuji Hosono1,2, Ran Nakashima1, Koji Kitagori1, Kosaku Murakami1, Hajime Yoshifuji1, Koichiro Ohmura3 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: Many kinds of autoantibodies are detected in idiopathic inflammatory myopathy (IIM) patients. Some of them are useful to diagnose, predict the clinical course, and…
  • Abstract Number: 1344 • 2018 ACR/ARHP Annual Meeting

    Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States

    Yuji Hosono1, Iago Pinal-Fernandez1, Katherine Pak1, Jemima Albayda2, Eleni Tiniakou3, Julie J. Paik4, Christopher A. Mecoli5, Sonye K. Danoff6, Lisa Christopher-Stine6 and Andrew Mammen1,7, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, 6Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 7Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies are common among Japanese dermatomyositis (DM) and clinically amyopathic DM (CADM) patients who develop rapidly progressive interstitial lung…
  • Abstract Number: 1551 • 2018 ACR/ARHP Annual Meeting

    Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases

    Johanna Gehin1, Guro Løvik Goll2, Silje Watterdal Syversen2, David J Warren1, Joseph Sexton3, Eldri Kvein Strand4, Tore Kvien5, Elisabeth Lie2 and Nils Bolstad6, 1Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Lillehammer Revmatismesykehus, Lillehammer, Norway, 5NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, 6Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway

    Background/Purpose: Anti-drug antibodies (ADAb) to biological drugs predispose patients (pts) to low drug levels and lack of treatment response. For certolizumab pegol (CP) knowledge about…
  • Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting

    Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis

    Svetlana I. Nihtyanova1, Alper Sari2, Voon H. Ong3 and Christopher P. Denton4, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Division of Medicine, University College London, London, United Kingdom, 4University College London, London, United Kingdom

    Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
  • Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting

    Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis

    Svetlana I. Nihtyanova1, Alper Sari2, Anna Leslie3, Voon H. Ong4 and Christopher P. Denton5, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4Division of Medicine, University College London, London, United Kingdom, 5University College London, London, United Kingdom

    Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
  • Abstract Number: 1898 • 2018 ACR/ARHP Annual Meeting

    Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach

    Luis F. Perez-Garcia1,2, Irving O. Estevez-Garcia3, Ricardo Marquez-Velasco3, Pedro Iturralde4, Luis H. Silveira5 and Luis M. Amezcua-Guerra2,6,7, 1Rheumatology, Erasmus MC, Rotterdam, Netherlands, 2Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 3Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 4Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 5Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, 6Cardiovascular Research Laboratory, Unidad de Investigacion Traslacional, Universidad Nacional Autonoma de Mexico/Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 7Department of Health Care, Universidad Autonoma Metropolitana, Xochimilco, Mexico City, Mexico

    Background/Purpose: Long QT syndrome (LQTS) is an abnormal QT corrected (QTc) interval prolongation, strongly associated with increased risk of sudden death. Studies have associated LQTS…
  • Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting

    Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus

    Giuseppe Alvise Ramirez1,2,3,4, Hannah Cohen5,6, David A. Isenberg4,7 and Maria Efthymiou5, 1Università Vita-Salute San Raffaele, Milan, Italy, 2Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, 4Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 5Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, 6Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 7University College London, London, United Kingdom

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…
  • Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting

    Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis

    Christopher T. Ritchlin1, Joseph F. Merola2, Amanda M. Gellett3, Chen-Yen Lin3 and Talia Muram3, 1University of Rochester Medical Center, Rochester, NY, 2Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
  • Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting

    IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

    Irene Cecchi1, Massimo Radin2, Elena Rubini3, Ana Suárez4, Dario Roccatello5, Savino Sciascia6 and Javier Rodríguez-Carrio7, 1Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 2Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, 4Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, 5Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, 7Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain

    Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
  • Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting

    Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus

    Yu-Min Kuo1,2, Jenhao Chen3, Jean-san Chia4, Chiau-jing Jung5 and Song-Chou Hsieh6, 1Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan, 2Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 3Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital,Yunlin branch, Yunlin County, Taiwan, 4Graduate Institute of Immunology, National Taiwan University College of Medicine, Taipei, Taiwan, 5Department of Microbiology and Immunology, School of Medicine,, College of Medicine, Taipei Medical University, Taipei, Taiwan, 6National Taiwan University Hospital, Taipei, Taiwan

    Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology